1. Analysis of drug resistance gene variation of influenza A(H1N1) pdm09 virus in Huzhou City,Zhejiang Province
- Author
-
XU Deshun, ZHA Yunfeng, and LU Zhonghao
- Subjects
influenza virus ,a(h1n1) pdm09 ,drug resistance ,gene variation ,m protein ,neuraminidase ,Medicine - Abstract
ObjectiveTo investigate the mutation and genetic evolution of drug resistance gene of A(H1N1) pdm09 influenza pandemic strain in 2023 in Huzhou City, Zhejiang Province.MethodsRespiratory tract specimens from 2 influenza monitoring hospitals were collected for A(H1N1) pdm09 influenza virus nucleic acid detection. Positive specimens were inoculated with MDCK cells for influenza virus isolation and sequencing. DNA Star 7.1 software and Mega 4.0 software were used to analyze the neuraminidase (NA) enzyme active site and the amino acid sites related to drug resistance in M2 protein.ResultsNucleotide homology and amino acid homology of NA between the isolated and the vaccine strains were 98.87%‒99.22% and 98.94%‒99.36%, respectively. The nucleotide homology range of M gene was 99.07% to 99.85%, and the amino acid homology range was 99.02%‒99.94%. The isolates and vaccine strains belong to the evolutionary clades of 6B.1A.5a.2a. The amino acids at the key sites of the enzyme activity center of NA were still highly conserved, and the 9 key amino acid sites related to NA inhibitor resistance did not change, but some mutations occurred at the non-enzyme active sites in some popular strains. The 5 amino acid sites related to drug resistance of M2 protein were not replaced, but the 31st amino acid sites changed from serine to asparagine.ConclusionThe A(H1N1) pdm09 pandemic strain in Huzhou in 2023 has high homology with the 2023‒2024 vaccine strain recommended by WHO. All endemic strains are resistant to amantadines.
- Published
- 2024
- Full Text
- View/download PDF